3,399 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by Ballentine Partners LLC

Ballentine Partners LLC bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 3,399 shares of the medical research company’s stock, valued at approximately $232,000.

Other institutional investors also recently bought and sold shares of the company. Itau Unibanco Holding S.A. purchased a new stake in Exact Sciences during the 2nd quarter worth about $29,000. V Square Quantitative Management LLC purchased a new stake in Exact Sciences during the 3rd quarter worth about $47,000. EverSource Wealth Advisors LLC lifted its holdings in Exact Sciences by 92.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after buying an additional 340 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Exact Sciences by 48.4% during the 2nd quarter. GAMMA Investing LLC now owns 1,362 shares of the medical research company’s stock worth $58,000 after buying an additional 444 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in Exact Sciences during the 1st quarter worth about $67,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Stock Up 0.4 %

EXAS opened at $69.64 on Wednesday. The business has a 50 day moving average price of $66.20 and a two-hundred day moving average price of $56.42. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73. The company has a market cap of $12.85 billion, a PE ratio of -52.76 and a beta of 1.27. Exact Sciences Co. has a 52 week low of $40.62 and a 52 week high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, July 31st. The medical research company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.28. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The firm had revenue of $699.26 million during the quarter, compared to the consensus estimate of $690.02 million. During the same period in the prior year, the business earned ($0.45) EPS. The firm’s revenue was up 12.4% compared to the same quarter last year. As a group, research analysts anticipate that Exact Sciences Co. will post -0.87 EPS for the current year.

Insiders Place Their Bets

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the transaction, the executive vice president now owns 12,758 shares in the company, valued at approximately $893,060. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.36% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. The Goldman Sachs Group decreased their price target on Exact Sciences from $88.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, July 17th. Evercore ISI boosted their target price on Exact Sciences from $72.00 to $80.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus reduced their target price on Exact Sciences from $100.00 to $82.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Canaccord Genuity Group boosted their target price on Exact Sciences from $75.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Raymond James reissued a “market perform” rating on shares of Exact Sciences in a report on Thursday, September 26th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $79.92.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.